Finzati - Logo
BCDA logo

BioCardia, Inc.

BCDA • Biotechnology
$1.07
▲ +0.03 (+2.73%)
Current price
EarningsLatest report: Jun 30, 2026
WEAK PROFILEWeakConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$13.83M
Growth
-100.0%
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.59Negative growth trendWeak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:37 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$1.07
Change2.73%
Market Cap$13.83M
52W Range0.75 - 2.29
Beta0.49
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.59
Current Ratio1.12
Quick Ratio1.12
Revenue 5Y-100.00%

Investment DNA

How strong this company looks for long-term investors

28
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
58/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
26/100
Why this score▼
Manageable debt level · 0.59Negative growth trendWeak profitability
Analyst view
No analyst data available now.

Company Overview

IPO: 11/13/1996
Industry: Biotechnology
P/B i: 9.31
Debt / Equity i: 0.59
Operating Margin: 0.00%
Net Margin: 0.00%
ROE i: -
ROIC: -

Financial Health

Score12 / 20
Debt / Equity: 0.59
Current Ratio: 1.12
Quick Ratio: 1.12
Status: Good

Insider Transactions

Recent executive and insider activity

Altman Peter
Transaction: 08/13/2026
BUY
Change
+1,900
Price
$0.92
Filing
08/13/2026
Type
BUY
Altman Peter
Transaction: 07/29/2026
BUY
Change
+5,000
Price
$0.78
Filing
07/29/2026
Type
BUY
Altman Peter
Transaction: 07/17/2026
BUY
Change
+500
Price
$0.83
Filing
07/20/2026
Type
BUY